Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have you purchased and downloaded the article? If so you will find that it is a short (4 and 1/2 pages) summary article with 111 References. It was written by Fengping Shan and his colleagues at China Medical University, Shenyang, China. Name seem familiar-it should-Shan is the apparently unpaid (according to the latest IMUN SEC filings)CSO (Chief Scientific Officer) of IMUN. The addition of Griffin on this (as well as other publications by Shan) is laughable.
Even though there is definite technical information within this summary that may make difficult reading for some, in general this article SHOULD be read by all shareholders. I firmly believe this is the promised "Scientific White Paper" that was to be completed by the end of 2017 as stated by Griffin in her November 30, 2017 Shareholder Letter and should be made immediately available to all shareholders.
The cost to download from the Journal publisher is $37.95. Now logically you would think that IMUN should have this link to the full article on its website. You would think. No doubt a demand for such from shareholders is solidly in order. And a demand for full article to be posted ASAP!
Curious about the long ago announced "White Paper" on LDN? Well, I believe this is it and here is the link to the abstract of the published paper:
www.ncbi.nlm.nih.gov/pubmed/29885638
The inclusion of IMUN in the Research and Markets report is a least crazy. As stated earlier, it would be extremely interesting and very important to know the information that the report producing company has that would have led to their decision to add IMUN as one of the profiled companies covering this significant area of research and therapeutic potential. Hopefully it is more than in the five paragraphs of the April 21, 2016 press release related to the announcement of a Letter of Intent to acquire the purported Chinese CAR-T Technology and Clinical Data.
Perhaps I need to be clearer. If in the report that we have been discussing the data indicates definitive and credible progress with the purported Chimeric Super Antigen Receptor T-Cell cocktail therapy promulgated by Professor Fengping Shan and his team, that unto itself would be some real PR. And the PPS should significantly exceed the 0.06-0.10 you indicated.
Pragmatism dictates that one should actually read the report and determine what is reported re: IMUN. If you have done so it would be super to share the information. Or, if not, perhaps someone will be willing to fork out the $4,500.00 plus shipping to obtain the report and then report on the information re: IMUN. That would be most informative-for all.
IF IMUN is listed in such report, and many in the field become interested what will they find in their obvious DD based on eagerness to obtain information about IMUN's CAR-T technology.
It is the purported Chimeric Super Antigen Receptor T cell cocktail therapy promulgated by Professor Fengping Shan. Has anyone heard of any progress made on this over last two years?
One thing to be listed with the types of corporations in the report-but another to be able to credibly demonstrate some interesting potential therapy results. Are there any? If there are, why has this not been reported, This is as the report title states "..The Most Hot Topic Discussed Among Oncologists Throughout The Globe."
Do you want the stock value to be increased? What has been happening? Any presentations at scientific meetings? Any publications of any nature covering this purported CAR-T cocktail therapy? Must be-IMUN is in the report.
Now here's one that might have blown by all the PR discussion. Important for all IMUN shareholders to contemplate. This astute poster, to whom I am responding, provided a link to an announcement on the prnewswire of a Research and Markets report publication and availability titled "CAR-T Cell Therapy Market 2016-2026:The Most Hot Topic Discussed Among Oncologists Throughout the Globe." And low and behold who is listed under one of nine company profiles --Immune Therapeutics. Alongside the likes of Celgene, Juno Therapeutics, Kite Pharma (purchased last year by Gilead Sciences for $12 Billion) Novartis AG and Sorrento Therapeutics.
Unfortunately, these marketing compilations have a hefty price tag and so does this -$ 4,500.00. But it sure begs the curiosity-how and why was IMUN selected? Based on what?
Just my own curiosity and sure should be all of yours. IMO, much better fodder for investigation than trying to get credible info from Ms. Gina, Esq.
Interesting and important question that you have posed to CannaZoid. In reading further down in the posting to which you refer the poster states "I've had the pleasure of sitting in on a group conversation with Noreen a while ago."
Definite added question would be when and what was the group opportunity you had to sit with Griffin?
That is correct. FDA approval required for sales/distribution in the USA. In other countries FDA approval is only needed if the individual country requires such approval for a specific drug or in general.
As an aside, your indicated continuing DD is needed and most helpful.
Well if LA did make some inquiry about what you purport to have seen earlier this week on the Cytocom, Inc, website it would be most informative to know what the answers were to some questions about the apparent temporary listings on the Cytocom, Inc. website opening home page and to whom such inquiry was made. You state nobody is being told anything right now-is that what happened to LA-he was not told anything in response to his questions?
Also, one of the most important questions that LA should have made that is directly related and extremely pertinent--What happened to John H. Abeles, M.D.
I have no idea what Cytocom, Inc. website you are looking at but I just checked at www.cytocom.com and as has been and still is under Management there is Noreen Griffin listed as President. And except for nothing anymore about Chairman of the Board and CEO John H. Abeles, M.D. there is absolutely no other updates. None. Is there another website for Cytocom??
Thank you for your response. Appears that when you said removed you were referring to his name and all the attendant information about him being removed from the Cytocom website. In this case it isn't just bad PR and little or no communication. I strongly believe an SEC 8-K should have been made-at least stating at the very minimum he was no longer with the Cytocom. Why?? Because the 8-K filing of March 28, 2018 covering the purported receipt of Minutes From FDA Meeting for Lodonal for the Treatment for Crohn's Disease announcement came from IMUN and the wording in the announcement contained several clearly direct tie ins between IMUN and Cytocom. And Cytocom CEO Abeles was quoted with significant statements regarding the outcome of the January 16, 2018 FDA Meeting. What happened? Where is he? Not only more obfuscation, but required SEC filing negligence.
Would most appreciate to know who is the WE that "...have already had questions and discussions about that." Do you mean questions and discussions here on this posting site. Your inference is that there was somewhat extensive back and forth as to the Abeles removal as you state. Do you have information that he was removed and did not resign his positions? Perhaps you have had discussion with John. OR someone at IMUN?
In reading this post, and the one previous that you posted, it is abundantly clear from your words that the progress and increased value of IMUN's potential will only happen when Griffin is fully replaced. That was the announcement back in November, 2017 and the deadline announced for replacement was stated as June 30, 2018-in nine days. And by fully replaced she should not be involved with Cytocom either. Remember, no matter all the discussion surrounding PR efforts, etc.,etc., all that and other failures stops where it should--at the desk of any CEO, I repeat any CEO- whether public or private company.
Look at the link to the stock chart a poster placed earlier today-note the nose dive in stock valuation and continuing depressed value since July, 2013 to today. NO CEO survives any of that!
If you are indicating that "one of the few updated things on the Cytocom site.." is Griffin as CEO that does not appear to be correct. Griffin is still shown to be President as previously indicated. What is updated is the complete absence of John H. Abeles, M.D. as Chairman of the Board of Directors and CEO. On August 25, 2017 an IMUN 8-K release indicated the Abeles appointment to ..."Spearhead Aggressive, Yet Systemic, Expansion Strategy across Africa and other countries much faster than initially anticipated". No 8-K this time explaining his apparent departure from Cytocom.
Sure would be extremely interesting to see what the report says about Immune Therapeutics and CAR-T Cell Therapy.
Check the Cytocom, Inc. web site under Management. It now lists only Griffin as President, Peter Aronstam as CFO and Fengping Shan as the CSO. The information on Abeles as Chairman of the Board and CEO is no longer there. In addition, if you remember on the IMUN web site there was a photo of Abeles that appeared as part of the display accompanying announcements. That is also gone. Where is Dr. Abeles?
Great phrase!..."see if there is something behind the curtain". One peek behind the curtain for all who have invested should be--What happened to John Abeles, M.D.--remember him. Brought in with great declarations as the Chairman of the Board and CEO of Cytocom, Inc. as well as a Senior Advisor to IMUN. Now what?
Simple question-and where is the funding to allow Cytocom, Inc. to pursue the necessary clinical studies for potential therapy in Crohn's Disease as required and defined by the FDA? Where?
There is an update on the Cytcom, Inc. website. Interesting change-no more John Abeles, M.D., Chairman of the Board and CEO. Back to Broadway.
Precisely-the obvious question! Thank you! I checked the 2017 10K and it indicates an ownership in Cytocom,Inc. by IMUN as of 12/31/17 of 9.3%. So the correct conclusion would be that based on the wording in the release yesterday it appears there will now be a 19.3% ownership of Cytocom, Inc. by IMUN. It appears that is so. But, abracadabra!
What have you read??
It seems to me that IMUN has to file an 8-K delineating the detailed particulars of " The amended and restated license agreement (with Cytocom, Inc. in 2014) was entered in conjunction with a stock purchase agreement where the Company agreed to acquire 10% of Cytocom's issued and outstanding common stock in exchange for cancellation of approximately $ 4,100,000 of debt owed by Cytocom to the Company." The details should include when the company provided those monies.
First, it seems that since yesterday many are either not understanding and are just not stating correctly the IMUN ownership of Cytocom, Inc. Not surprising since the wording in yesterday's obfuscatory PR notice did not explain that an additional 10% stake is to be made. I believe there is an under 10 % ownership in existence per the info in the 2017 10K (and one has to take that on face value) so the proper wording is an additional 10% stake In Cytocom, Inc. is to be completed.
Second, once again I definitely disagree with your analysis of Griffin and her purported accomplishments. Just reading all of your frustrated and detailed postings concerning the appropriate manner to issue substantive and most important credible news releases to attract needed interest from potential new shareholders points to naivete or incompetence on Griffin's part. I firmly choose the latter.
Third, and I will follow up on this again--since Cytocom, Inc. has apparently now come front and center and emerged from the fog of uncertainty, I am curious how many that post herein are actual direct owners. Obviously I am not asking for any disclosure of share amounts, but for those that are willing to indicate " I am" would be interesting to note for all. I'll start--"I am ".
Once again I must highly compliment you on an truly outstanding summary.The only strong disagreement I have with the posting is your indication that you believe Griffin is intelligent. Over the years to date she has been fully unqualified to be CEO of a biotechnology company and the proof is in the pudding in many, many ways. No doubt she participated in the writing and/or the proof reading (or some competent person should hsve been assigned to the proof reading) of the released missive this morning--just look at the spelling of one of the only two products the company has-the correct spelling is Met-Enkephalin (NOT Met-Enkelphline). Not only once but twice in the release. And this is not the first public release the same has occurred. Complete reflection on the company.
Your WHY?? questions are on target!
Thank you very much for this reply! It is probably one of the most significant postings to date, if not the most significant! My only initial question is: When and how did you receive this letter addressed to shareholder?? I am a shareholder and to date have not received this letter.
Again appreciate the posting and I await your answer.
Some may be "confused" but I am not! The Cytocom, Inc. historical establishment is and has been clearly described in the IMUN filings. And you are totally incorrect in indicating that they are "completely separate, and one is not a subsidiary of the other."
Cytocom, Inc. is and always has been a subsidiary of IMUN with a significant connection- even though now a minority owned subsidiary having attained that status through some incompletely explained dilution.
Fund sourcing in place for LDN clinical studies?? The heralded John Abeles, M.D., the purported Chairman of the Board and CEO of Cytocom, Inc. needs to step forward and provide some substantive information.
Thank you. I was aware of the Phase 1 and Phase 2 type studies actually performed by Jill Smith, M.D. and colleagues at Penn State. I just wanted accuracy regarding information provided in these postings. Added info-noted in the public filings the agreement between Dr. Smith and her group and IMUN known as the "Smith Agreement" was signed on December 24, 2012-well over 5 years ago!
One major question! What Phase 1 and Phase 2 clinical trials were performed by Cytocom?? And when??
Some needed corrections for accuracy purposes. First, the LDN Crohn's clinical study to which I referred was performed by another research group in the Netherlands and not at what I believe you really meant-Pennsylvania State University NOT University of Pennsylvania that you indicated(UPenn). The study was both a clinical endpoint study and a mechanistic study designed to (1) attempt to define the mechanism of the observed clinical effect(s) (2) examine any other effects that has bearing on the observed positive clinical outcome.
Food for thought-Eli Lilly just announced about 3 hours ago that it is buying for $1.6 Billion cash Armo BioSciences. Armo has a lead drug pegilodecakin that is the cytokine IL-10 and is in late stage clinical testing in pancreatic cancer and activates CD8+ T Cells. This cytokine has been tested on its own and in combination with chemotherapies and could very well be useful in combination therapy with a different immunotherapy.
Remember methionine enkephalin (MENK) anyone?
Please elucidate what you mean by "The market would react more positively if the study was not conducted by its biggest clinical proponent." To whom are you referring? And what in the study is "just more hot air"?
The first publication listed in the website that you posted last week was a very recent excellent European clinical study titled "Low Dose Naltrexone for Induction of Remission in Inflammatory Bowel Disease Patients". This study clearly supports the clinical work of Jill Smith, M.D., whose patent, titled " Treatment of Inflammatory and Ulcerative Diseases of the Bowel with Opioid Antagonists" is licensed to Cytocom, Inc. which is now only less than 10 % owned by IMUN. Everyone should be curious as to what the development status is after the FDA Meeting? Are funds becoming available to initiate the discussed LDN clinical studies with the FDA? What are the approximate time frames? Are the studies to be conducted under the auspices of Cytocom, Inc.?
Big Time Kudos to you for pointing out this online site for the message board members. It is most significant in many ways!
Curious as to your comment about Griffin putting out reports referring to "these University studies". Not sure what studies these are? Would be really informative if you can provide more detail, if you know, about these studies. Thank you.
Would you be willing to provide some further insight into your indicated speculation as to the reason for Akin's resignation from IMUN's Board because you were "coming after his livelihood".??
Has anyone else noted and checked the website www.antiaging systems.com. If not, do so--you will find interesting product advertised for purchase called Naltrexone (LDN, Nal-Pro), available in a box of 30x 4.5 mg capsules. Particularly indicated at this site for the treatment of Multiple Sclerosis(MS).
Does not IMUN possess patent for use in MS treatment? Assume IMUN "management" is on top of this for several obvious reasons.
Seems the Board of Directors is now down to three. As of March 31, 2018 the Board now consists of only Griffin, Clifford Selsky and Edward Teraskiewicz. Paul Akin resigned from the Board effective that date as indicated in the 2017 Annual Report.